Varenicline is a smoking cessation drug that blocks alveolar expansion in mice intratracheally administrated porcine pancreatic elastase

被引:7
作者
Koga, Mitsuhisa [1 ]
Kanaoka, Yuki [1 ]
Tashiro, Tetsushi [1 ]
Hashidume, Nagisa [1 ]
Kataoka, Yasufumi [1 ]
Yamauchi, Atsushi [1 ]
机构
[1] Fukuoka Univ, Fac Pharmaceut Sci, Dept Pharmaceut Care & Hlth Sci, Fukuoka, Fukuoka 8140180, Japan
关键词
Varenicline; Emphysema; Inflammatory cells; NICOTINIC ACETYLCHOLINE-RECEPTOR; PARTIAL AGONIST; ALPHA-4-BETA-2; CELLS; EFFICACY; PLACEBO; DISEASE;
D O I
10.1016/j.jphs.2018.06.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Smoking cessation is the most effective treatment in patients with emphysema and lung inflammation. The aim of the present study was to examine the effect of varenicline, a smoking cessation drug, on emphysema in porcine pancreatic elastase (PPE)-inhaled mice. PPE-inhaled mice were treated with varenicline and an alpha 7 nicotinic acetylcholine receptor (nAChR) antagonist, methyllycaconitine (MLA) for 5 and 21 days. Varenicline markedly ameliorated alveolar expansion and inflammatory response in bronchoalveolar lavage fluid in PPE-inhaled mice. These blocking effects were inhibited by MLA. Our findings demonstrate that varenicline likely has an anti-inflammatory property including reduced inflammatory cell recruitment in lung tissue to protect PPE-induced alveolar expansion via alpha 7 nAChR. (c) 2018 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
引用
收藏
页码:224 / 229
页数:6
相关论文
共 15 条
  • [1] Alpha7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases
    Bencherif, Merouane
    Lippiello, Patrick M.
    Lucas, Rudolf
    Marrero, Mario B.
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2011, 68 (06) : 931 - 949
  • [2] Sustained CTL activation by murine pulmonary epithelial cells promotes the development of COPD-like disease
    Borchers, Michael T.
    Wesselkamper, Scott C.
    Curull, Victor
    Ramirez-Sarmiento, Alba
    Sanchez-Font, Albert
    Garcia-Aymerich, Judith
    Coronell, Carios
    Lloreta, Josep
    Agusti, Alvar G.
    Gea, Joaquim
    Howington, John A.
    Reed, Michael F.
    Starnes, Sandra L.
    Harris, Nathaniel L.
    Vitucci, Mark
    Eppert, Bryan L.
    Motz, Gregory T.
    Fogel, Kevin
    McGraw, Dennis W.
    Tichelaar, Jay W.
    Orozco-Levi, Mauricio
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (03) : 636 - 649
  • [3] Chronic Obstructive Pulmonary Disease 1 New insights into the immunology of chronic obstructive pulmonary disease
    Brusselle, Guy G.
    Joos, Guy F.
    Bracke, Ken R.
    [J]. LANCET, 2011, 378 (9795) : 1015 - 1026
  • [4] Varenicline:: An α4β2 nicotinic receptor partial agonist for smoking cessation
    Coe, JW
    Brooks, PR
    Vetelino, MG
    Wirtz, MC
    Arnold, EP
    Huang, JH
    Sands, SB
    Davis, TI
    Lebel, LA
    Fox, CB
    Shrikhande, A
    Heym, JH
    Schaeffer, E
    Rollema, H
    Lu, Y
    Mansbach, RS
    Chambers, LK
    Rovetti, CC
    Schulz, DW
    Tingley, FD
    O'Neill, BT
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (10) : 3474 - 3477
  • [5] Physiological functions of the cholinergic system in immune cells
    Fujii, Takeshi
    Mashimo, Masato
    Moriwaki, Yasuhiro
    Misawa, Hidemi
    Ono, Shiro
    Horiguchi, Kazuhide
    Kawashima, Koichiro
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2017, 134 (01) : 1 - 21
  • [6] Fujita Tetsuo, 2016, Biochem Biophys Rep, V7, P400, DOI 10.1016/j.bbrep.2016.07.010
  • [7] Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced and emphysema
    Ishii, Y
    Itoh, K
    Morishima, Y
    Kimura, T
    Kiwamoto, T
    Ilzuka, T
    Hegab, AE
    Hosoya, T
    Nomura, A
    Sakamoto, T
    Yamamoto, M
    Sekizawa, K
    [J]. JOURNAL OF IMMUNOLOGY, 2005, 175 (10) : 6968 - 6975
  • [8] Twelve Weeks of Successful Smoking Cessation Therapy with Varenicline Reduces Spirometric Lung Age
    Iwaoka, Masahiko
    Tsuji, Takeshi
    [J]. INTERNAL MEDICINE, 2016, 55 (17) : 2387 - 2392
  • [9] Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation -: A randomized controlled trial
    Jorenby, Douglas E.
    Hays, J. Taylor
    Rigotti, Nancy A.
    Azoulay, Salomon
    Watsky, Eric J.
    Williams, Kathryn E.
    Billing, Clare B.
    Gong, Jason
    Reeves, Karen R.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (01): : 56 - 63
  • [10] IL-17A is essential to the development of elastase-induced pulmonary inflammation and emphysema in mice
    Kurimoto, Etsuko
    Miyahara, Nobuaki
    Kanehiro, Arihiko
    Waseda, Koichi
    Taniguchi, Akihiko
    Ikeda, Genyo
    Koga, Hikari
    Nishimori, Hisakazu
    Tanimoto, Yasushi
    Kataoka, Mikio
    Iwakura, Yoichiro
    Gelfand, Erwin W.
    Tanimoto, Mitsune
    [J]. RESPIRATORY RESEARCH, 2013, 14